Milana FRENKEL-MORGENSTERN

//
//
Milana FRENKEL-MORGENSTERN
Milana FRENKEL-MORGENSTERN
Milana FRENKEL-MORGENSTERN
WG5 Leader
Bar-Ilan University
Henrietta Szold 8
Safed, Israel

Dr. Milana Frenkel-Morgenstern research interest is in strategy to identify unique potential drug targets in cancer cells. The drug targets we are looking for are abnormal fusion transcripts, also known as “chimeric RNAs,” that can be shown to exist only, or predominantly, in various cancer cells. Dr. Frenkel-Morgenstern catalogues these cancer-associated fusion transcripts, then she analyses the function of the proteins produced by the transcripts in order to find potential drug targets. The key challenge is to identify those fusion events that are directly related to biochemical cell function.